Illumina (NASDAQ:ILMN) Issues Earnings Results

Illumina (NASDAQ:ILMN) announced its quarterly earnings data on Thursday. The life sciences company reported $0.09 EPS for the quarter, beating the consensus estimate of $0.04 by $0.05, RTT News reports. Illumina had a positive return on equity of 2.20% and a negative net margin of 25.78%. The business had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.05 billion. During the same quarter last year, the firm posted $0.08 earnings per share. The company’s revenue for the quarter was down 1.0% on a year-over-year basis.

Illumina Price Performance

Shares of Illumina stock traded down $0.69 during trading on Thursday, reaching $123.99. 1,627,083 shares of the stock traded hands, compared to its average volume of 1,697,142. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.66 and a quick ratio of 1.29. The company has a market capitalization of $19.75 billion, a price-to-earnings ratio of -16.99 and a beta of 1.20. Illumina has a 52-week low of $89.00 and a 52-week high of $213.91. The business has a fifty day simple moving average of $130.57 and a two-hundred day simple moving average of $127.14.

Insider Buying and Selling

In other news, CEO Jacob Thaysen acquired 7,330 shares of Illumina stock in a transaction on Thursday, February 22nd. The shares were acquired at an average price of $135.29 per share, with a total value of $991,675.70. Following the purchase, the chief executive officer now directly owns 14,861 shares in the company, valued at approximately $2,010,544.69. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.17% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ILMN. OTR Global reissued a “mixed” rating on shares of Illumina in a research note on Wednesday, March 20th. TD Cowen cut Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 price target on the stock. in a research report on Thursday, January 4th. HSBC lowered Illumina from a “buy” rating to a “hold” rating in a research report on Tuesday, January 16th. Barclays boosted their target price on Illumina from $85.00 to $100.00 and gave the stock an “underweight” rating in a report on Wednesday, April 10th. Finally, StockNews.com upgraded Illumina from a “hold” rating to a “buy” rating in a report on Friday, February 16th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $167.70.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.